Coach vs. Kors: Bat...
Health Care: Drugs
Discovery Laboratories Inc. (DSCO: NASDAQ)
$2.50 -0.02 | -0.79%
06/04/12 - 09:34 AM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 10.19M | 10.21M | 15.74M | 22.74M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 10.63M | 10.50M | 15.97M | 25.42M |
| Property, Plant & Equipment, Gross | 11.12M | 11.06M | 10.89M | 10.75M |
| Accumulated Depreciation & Depletion | 8.82M | 7.59M | 6.23M | 4.78M |
| Property, Plant & Equipment, Net | 2.29M | 3.47M | 4.67M | 5.96M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 400.00K | 574.00K | 761.00K | 1.51M |
| Total Non-Current Assets | 2.69M | 4.04M | 5.43M | 7.47M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 13.32M | 14.54M | 21.40M | 32.89M |
| Accounts Payable | 1.11M | 1.68M | 1.29M | 2.11M |
| Short Term Debt | 68.00K | 136.00K | 11.06M | 2.44M |
| Other Current Liabilities | 7.00M | 2.47M | 0.00 | 0.00 |
| Total Current Liabilities | 11.15M | 7.58M | 15.80M | 9.87M |
| Long Term Debt | 0.00 | 0.00 | 428.00K | 11.22M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 689.00K | 634.00K | 690.00K | 870.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 913.00K | 935.00K | 1.12M | 12.09M |
| Total Liabilities | 12.06M | 8.51M | 16.92M | 21.96M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 1.26M | 6.03M | 4.49M | 10.93M |
| Common Par | 25.00K | 14.00K | 127.00K | 102.00K |
| Additional Paid In Capital | 401.71M | 385.52M | 365.06M | 341.29M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -397.42M | -376.46M | -357.65M | -327.41M |
| Treasury Stock | -3.05M | -3.05M | -3.05M | -3.05M |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 1.00K |
| Total Capitalization | 1.26M | 6.03M | 4.92M | 22.15M |
| Total Equity | 1.26M | 6.03M | 4.49M | 10.93M |
| Total Liabilities & Stock Equity | 13.32M | 14.54M | 21.40M | 32.89M |
| Total Common Shares Outstanding | 24.58M | 13.80M | 8.43M | 6.84M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 21.00K | 21.00K | 20.87K | 20.87K |
| Basic Weighted Shares Outstanding | 22.66M | 11.60M | 7.68M | 6.54M |
| Diluted Weighted Shares Outstanding | 22.66M | 11.60M | 7.68M | 6.54M |
| Number of Employees | 70 | 67 | 77 | 118 |
| Number of Part-Time Employees | 3 | 2 | 0 | 0 |
Portfolios with DSCO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserSmall Cap Stocks
- UserKJP Spring Break
- Userjet189 Portfolio 1
- Uservolume spike
- Usermoon_in_mood Portfolio 1
- UserDtech Portfolio 1
- UserLizann
- UserBNunnally Portfolio 1
- Usershaldar Portfolio 1
Latest DSCO Headlines from TheStreet
- 5 Stocks Under $10 Poised for Upside 04.27.12 | 11:04 am
- For Biotech Takeovers, Timing is Key 04.04.12 | 06:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- Market Preview: The Bulls Finally Blink (Correct) 03.06.12 | 10:03 pm
- Pandora, Discovery Labs: After-Hours Trading (Update 1) 03.06.12 | 08:03 pm
- The Next Big Thing in Biotech: Discovery Labs
03.02.12 | 06:03 am - Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash 03.02.12 | 05:03 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
Press Releases for DSCO
- Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated With Reintubation In Premature Infants - PR Newswire 05.01.12 | 07:05 am
- Media Alert: Discovery Labs To Hold Conference Call To Discuss FDA Approval Of SURFAXIN® (lucinactant) - PR Newswire 03.07.12 | 07:03 am
- Discovery Labs Announces FDA Approval Of SURFAXIN® (lucinactant) For Prevention Of Respiratory Distress Syndrome - PR Newswire 03.06.12 | 04:03 pm
- Discovery Labs Signs Manufacturing Agreement For AFECTAIR® - PR Newswire 02.08.12 | 07:02 am
- Discovery Labs Cleared To Market AFECTAIR In U.S. - PR Newswire 02.02.12 | 07:02 am
- New Study Shows AFECTAIR® Significantly Improved Delivery Of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions - PR Newswire 12.06.11 | 08:12 am
- Discovery Labs Releases New AFECTAIR⢠Performance Data Presented At The American Association For Respiratory Care Annual Meeting - PR Newswire 11.08.11 | 08:11 am
- New Study Shows Neonatologists And Parents Of NICU Infants Share Concern Regarding Newborn Exposure To Animal-Derived Medications - PR Newswire 10.18.11 | 07:10 am
- Discovery Labs Notified Of PDUFA Date For SURFAXIN® - PR Newswire 09.28.11 | 12:09 pm
- Discovery Labs Submits SURFAXIN® Complete Response To FDA - PR Newswire 09.06.11 | 07:09 am
Partner Headlines for DSCO
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Discovery Labs Down 17% After Public Offering Announcement - Benzinga 03.16.12 | 09:03 am
- Company News for March 8, 2012 - Corporate Summary - Zacks 03.08.12 | 10:03 am
- Discovery Labs Up 33% After Surfaxin Approved by the FDA - Benzinga 03.07.12 | 09:03 am
- Discovery Labs Announces FDA Approval of SURFAXIN for Prevention of Respiratory Distress Syndrome - Benzinga 03.06.12 | 04:03 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- UPDATE 1-Discovery Labs' cystic fibrosis drug gets orphan status - Reuters 11.01.10 | 08:11 am
- UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial - Reuters 06.09.10 | 08:06 am
- FDA, Clinical Trial News: Discovery Labs, Hospira, Javelin Pharma - Seeking Alpha 05.20.10 | 06:05 am
